![Thomas Meier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Meier
Founder at
SANTHERA PHARMACEUTICALS HOLDING AG
Net worth: 1 M $ as of 30/07/2026
Profile
Thomas Meier was the founder of MyoContract AG, founded in 2000, where the title held was Chief Executive Officer from 2000 to 2004.
Dr. Meier is the founder of Santhera Pharmaceuticals Holding AG, founded in 2004, holding the title of Chairman since 2022.
Dr. Meier is the founder of Seal Therapeutics AG, founded in 2021, holding the title of Chairman since 2021.
Current jobs include Executive Chairman at Novaremed AG since 2024, Chairman at PharmaBiome AG since 2020, Director at Visgenx, Inc. since 2022, and Managing Partner at Viopas Venture Consulting GmbH.
Former job includes Director at Onconetix, Inc. from 2024 to 2026.
Education includes a doctorate conferred in 1992 and a graduate degree from the University of Basel.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/12/2025 | 62,501 ( 0.4% ) | 1 M $ | 30/07/2026 | |
| 12/03/2026 | 13 ( 0% ) | 11 $ | 30/07/2026 |
Thomas Meier active positions
| Companies | Position | Start |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Founder | 06/09/2004 |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Develops safer and more efficacious drugs for chronic and life-threatening diseases | Chairman | 31/12/2023 |
PharmaBiome AG
 PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services Develop novel platform technologies to formulate microbiota transplant products | Chairman | 30/06/2020 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Corporate Officer/Principal | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Director/Board Member | 31/12/2021 |
Former positions of Thomas Meier
| Companies | Position | End |
|---|---|---|
| ONCONETIX, INC. | Director/Board Member | 19/04/2026 |
MyoContract AG
 MyoContract AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for muscle disorders | Chief Executive Officer | 31/12/2003 |
Training of Thomas Meier
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
64
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
MyoContract AG
MyoContract AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for muscle disorders | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Develops safer and more efficacious drugs for chronic and life-threatening diseases | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services Develop novel platform technologies to formulate microbiota transplant products | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Health Technology |
Onconetix, Inc.
 Onconetix, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology drugs and diagnostic test for cancers | Health Technology |
- Stock Market
- Insiders
- Thomas Meier
